Antidepressants and the cardiac patient

References

• American Medical Association, Division of Drugs and Technology, in cooperation with the American Society for Clinical Pharmacology and Therapeutics. Drug evaluations. 6th ed. Philadelphia: WB Saunders. 1986: 135, 138
   Google Scholar
• Roose SP, Glassman AH, Glardina EG, et al. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987: 44(3): 273–5
   PubMed Web of Science ®Google Scholar
• Hayes JR, Born GF, Rosenbaum AH. Incidence of orthostatic hypotension in patients with primary affective disorders treated with tricyclic antidepressants. Mayo Clin Proc 1977: 52(8): 509–12
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Qultkin FM, McGrath P, et al. Adverse reactions to monoamine oxidase inhibitors. Part II: treatment correlates and clinical management. J Clin Psychopharmacol 1985: 5(1): 2–9
   PubMed Web of Science ®Google Scholar
• U'Prichard DC, Greenberg DA, Sheehan PP, et al. Tricyclic antidepressants: therapeutic properties and affinity for alpha-noradrenergic receptor binding sites in the brain. Science 1978: 199(4325): 197–8
   PubMed Web of Science ®Google Scholar
• Rudorfer MV, Young RC. Desipramine: cardiovascular effects and plasma levels. Am J Psychiatry 1980: 137(8): 984–6
   PubMed Web of Science ®Google Scholar
• Kronig MH, Roose SP, Walsh BT, et al. Blood pressure effects of phenelzine. J Clin Psychopharmacol 1983: 3(5): 307–10
   PubMed Web of Science ®Google Scholar
• Glassman AH, Johnson LL, Giardina EG, et al. The use of imipramine in depressed patients with congestive heart failure. JAMA 1983: 250(15): 1997–2001
   PubMed Web of Science ®Google Scholar
• Glassman AH, Bigger JT Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants: a review. Arch Gen Psychiatry 1981: 38(7): 815–20
   PubMed Web of Science ®Google Scholar
• Goldman LS, Alexander RC, Luchins DJ. Monoamine oxidase inhibitors and tricyclic antidepressants: comparison of their cardiovascular effects. J Clin Psychiatry 1986: 47(5): 225–9
   PubMed Web of Science ®Google Scholar
• Pollack MH, Rosenbaum JF. Management of antidepressant-induced side effects: a practical guide for the clinician. J Clin Psychiatry 1987: 48(1): 3–8
   PubMed Web of Science ®Google Scholar
• Snyder SH, Yamamura HL. Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 1977: 34(2): 236–9
   PubMed Web of Science ®Google Scholar
• Razani J. White KL, White J, et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment: a controlled trial. Arch Gen Psychiatry 1983: 40(6): 657–61
   PubMed Web of Science ®Google Scholar
• Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985: 46(3 Pt 2): 42–4
   PubMed Web of Science ®Google Scholar
• Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986: 32(6): 481–508
   PubMed Web of Science ®Google Scholar
• Luchins DJ. Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants. Am J Psychiatry 1983: 140(8): 1006–9
   PubMed Web of Science ®Google Scholar
• Domovic P, Burrows GD, Vohra J, et al. The effect of tricyclic antidepressant drugs on the heart. Arch Toxicol 1976: 35(4): 255–62
   PubMed Web of Science ®Google Scholar
• Langou RA. Van Dyke C, Tahan SR, et al. Cardiovascular manifestations of tricyclic antidepressant overdose. Am Heart J 1980: 100(4): 458–64
   PubMed Web of Science ®Google Scholar
• Georgotas A, Cooper T, Kim M, et al. The treatment of affective disorders in the elderly. Psychopharmacol Bull 1983: 19(2): 226–37
   PubMedGoogle Scholar
• Robinson DS, Nies A, Corcella J, et al. Cardiovascular effects of pheneizine and amitriptyline in depressed outpatients. J Clin Psychiatry 1982: 43(5 Pt 2): 8–15
   PubMed Web of Science ®Google Scholar
• van de Merwe TJ, Silverstone T, Ankier SI, et al. A double-blind non-crossover placebo-controlled study between group comparison of trazodone and amitriptyline on cardiovascular function in major depressive disorder. Psychopathology 1984: 17(Suppl 2): 64–76
   PubMedGoogle Scholar
• Cohn JB, Wilcox C. A comparison of fluoxetine. Imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985: 46(3 Pt 2): 26–31
   PubMed Web of Science ®Google Scholar
• Jackson WK, Roose SP, Glassman AH. Cardiovascular toxicity of antidepressant medications. Psychopathology 1987: 20(Suppl 1): 64–74
   PubMed Web of Science ®Google Scholar
• Cassem NH. Depression. In: Hackett TP. Cassem NH. eds. Massachusetts General Hospital handbook of general hospital psychiatry. 2d ed. Littleton. MA: PSG/Wright Publishing. 1987: 227–60
   Google Scholar
• Connolly SJ, Mitchell LB, Swerdlow CD, et al. Clinical efficacy and electrophysiology of imipramine for ventricular tachycardia. Am J Cardiol 1984: 53(4): 516–21
   PubMed Web of Science ®Google Scholar
• Ahles S, Gwirtsman H, Halaris A, et al. Comparative cardiac effects of maprotiline and doxepin in elderly depressed patients. J Clin Psychiatry 1984: 45(11): 460–5
   PubMed Web of Science ®Google Scholar
• Pohl R, Bridges M, Rainey JM Jr, et al. Effects of trazodone and desipramine on cardiac rate and rhythm in a patient with preexisting cardiovascular disease. (Letter) J Clin Psychopharmacol 1986: 6(6): 380–1
   PubMed Web of Science ®Google Scholar
• Cassem N. Cardiovascular effects of antidepressants. J Clin Psychiatry 1982: 43(11 Pt 2): 22–9
   PubMed Web of Science ®Google Scholar
• Veith RC, Raskind MA, Caldwell JH, et al. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. N Engl J Med 1982: 306(16): 954–9
   PubMed Web of Science ®Google Scholar
• Gilman AG, Goodman LS, Rail TW, et al, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985
   Google Scholar
• Jefferson JW. A review of the cardiovascular effects and toxicity of tricyclic antidepressants. Psychosom Med 1975: 37(2): 160–79
   PubMed Web of Science ®Google Scholar
• Lippmann S. Drug therapy for depression in the elderly. Postgrad Med 1983: 73(1): 159–73
   PubMed Web of Science ®Google Scholar
• Sjöqvist F. A pharmacokinetic approach to the treatment of depression. Int Pharmacopsychiatry 1971: 6(3): 147–69
   PubMedGoogle Scholar
• Boyer WF, Friedel RO. Antidepressant and antipsychotic plasma levels. Psychiatr Clin North Am 1984: 7(3): 601–10
   PubMed Web of Science ®Google Scholar
• Amsterdam J, Brunswick D, Mendels J. The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. Am J Psychiatry 1980: 137(6): 653–62
   PubMed Web of Science ®Google Scholar
• Friedel RO, Raskind MA. Relationship of blood levels of sinequan to clinical effects in the treatment of depression in aged patients. In: Mendels J. ed. Symposium on sinequan (doxepin HCI) New York: Elsevier Science Publishing (Excerpta Medica), 1975: 51–3
   Google Scholar